CDC37在胃癌患者中的表达与临床病理特征及预后的关系-现代医学

CDC37在胃癌患者中的表达与临床病理特征及预后的关系

单位：1. 隆昌市人民医院普通外科, 四川隆昌 642150;
2. 隆昌市人民医院神经内科, 四川隆昌 642150

分类号：R735.2

出版年·卷·期（页码）：2025·53·第九期（1466-1472）

摘要：

目的： 探讨细胞分裂周期蛋白37(CDC37)在胃癌患者肿瘤组织中的表达情况与临床病理特征和预后的关系。方法： 选择2014年1月至2018年12月间在本院行手术治疗的129例胃癌患者为研究对象。免疫组化法检测患者胃癌组织中CDC37表达情况，根据胃癌患者肿瘤组织中CDC37表达情况分为无/低表达组(n=61)和高表达组(n=68)。比较两组患者临床病理特征差异，采用多因素Cox回归分析胃癌患者预后的影响因素；UCSC Xena和GEPIA网站绘制不同CDC37表达的胃癌患者生存曲线，采用Kaplan-Meier绘制本院胃癌患者生存曲线。结果： N分期、CEA和CA199在CDC37无/低表达组和高表达组中比较，差异均有统计学意义(均P<0.05)。多因素Cox回归分析显示，T3+T4分期、低/未分化肿瘤、弥散型Lauren分型、CDC37无/低表达是影响胃癌患者预后生存的独立危险因素(P<0.05)。CDC37无/低表达组的5年总生存率低于CDC37高表达组。结论： CDC37无/低表达是胃癌患者预后的独立危险因素，与预后不良相关，可能在胃癌患者预后评估中发挥重要作用，有望成为胃癌治疗的新靶点。

Objective: To investigate the expression of cell division cycle 37(CDC37) in tumor tissues of gastric cancer patients and its relationship with clinicopathological features and prognosis. Methods: A total of 129 patients with gastric cancer who underwent surgical treatment in our hospital from January 2014 to December 2018 were selected as the research subjects. The expression of CDC37 in gastric cancer tissues was detected by immunohistochemistry. According to the expression level of CDC37 in tumor tissues of gastric cancer patients, they were divided into the none/low expression group(n=61) and the high expression group(n=68). The differences in clinicopathological characteristics between the two groups were compared. Multivariate Cox regression analysis was used to identify the influencing factors for the prognosis of gastric cancer patients. The UCSC Xena and GEPIA databases were used to plot survival curves of gastric cancer patients with different CDC37 expression levels, and Kaplan-Meier was applied to draw the survival curves of gastric cancer patients in our hospital. Results: There were statistically significant differences in N stage, CEA and CA199 between the CDC37 none/low expression group and the high expression group(all P<0.05). Multivariate Cox regression analysis showed that T3+T4 stage, low or undifferentiated tumors, diffuse type of Lauren classification, and none/low expression of CDC37 were independent risk factors affecting the prognosis of gastric cancer patients(P<0.05). The 5-year overall survival rate of the none/low expression group of CDC37 was lower than that of the high expression group. Conclusion: None/low expression of CDC37 is an independent risk factor for the prognosis of gastric cancer patients, which is associated with poor prognosis and may play an important role in the prognosis assessment of gastric cancer patients, and is expected to become a new target for the treatment of gastric cancer.

参考文献：

[1] YANG W J,ZHAO H P,YU Y,et al.Updates on global epidemiology,risk and prognostic factors of gastric cancer[J].World J Gastroenterol,2023,29(16):2452-2468.
[2] ARAI H,YANG Y,BACA Y,et al.Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer[J].Eur J Cancer,2024,201:113914.
[3] EGUCHI T,PRINCE T L,TRAN M T,et al.MZF1 and SCAND1 reciprocally regulate CDC37 gene expression in prostate cancer[J].Cancers,2019,11(6):792.
[4] KOU X,JIANG X,LIU H,et al.Simvastatin functions as a heat shock protein 90 inhibitor against triple-negative breast cancer[J].Cancer Sci,2018,109(10):3272-3284.
[5] WANG Z,WEI W,SUN C K,et al.Suppressing the CDC37 cochaperone in hepatocellular carcinoma cells inhibits cell cycle progression and cell growth[J].Liver Int,2015,35(4):1403-1415.
[6] 中华人民共和国国家卫生健康委员会医政医管局.胃癌诊疗指南(2022年版)[J].中华消化外科杂志,2022,21(9):1137-1164.
[7] SANO T,COIT D G,KIM H H,et al.Proposal of a new stage grouping of gastric cancer for TNM classification:International Gastric Cancer Association staging project[J].Gastric Cancer,2017,20(2):217-225.
[8] HAN B,ZHENG R,ZENG H,et al.Cancer incidence and mortality in China,2022[J].J Natl Cancer Cent,2024,4(1):47-53.
[9] GUO Q,XU J,HUANG Z,et al.ADMA mediates gastric cancer cell migration and invasion via Wnt/β-catenin signaling pathway[J].Clin Transl Oncol,2021,23(2):325-334.
[10] 孙志昂,程婉蓉,李旭,等.RHOJ在胃癌中的表达及其对预后的影响[J].现代医学,2024,52(9):1321-1329.
[11] 周谦,孟宁,刘晟楠,等.视神经萎缩症蛋白1在胃癌组织中的表达及其对胃癌细胞增殖及凋亡的影响[J].现代医学,2023,51(9):1227-1234.
[12] LI L,TAO X,LI Y,et al.CDC37L1 acts as a suppressor of migration and proliferation in gastric cancer by down-regulating CDK6[J].J Cancer,2021,12(11):3145-3153.
[13] SU X Q,YIN Z Y,JIN Q Y,et al.Allium vegetable intake associated with the risk of incident gastric cancer:a continuous follow-up study of a randomized intervention trial[J].Am J Clin Nutr,2023,117(1):22-32.
[14] SUN Y,LI Z,TIAN Y,et al.Development and validation of nomograms for predicting overall survival and cancer-specific survival in elderly patients with locally advanced gastric cancer:a population-based study[J].BMC Gastroenterol,2023,23(1):117.
[15] ZHU X D,HUANG M Z,WANG Y S,et al.XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer:an open-labeled,multicenter,randomized,prospective phase Ⅲ trial(EXELOX)[J].Cancer Commun,2022,42(4):314-326.
[16] 黄裕涵,孙国平.基于SEER数据库的Lauren分型胃腺癌患者的术前全身性治疗疗效分析[J].安徽医专学报,2023,22(4):20-23.
[17] CAMPS-FAJOL C,CAVERO D,MINGUILLÓN J,et al.Targeting protein-protein interactions in drug discovery:modulators approved or in clinical trials for cancer treatment[J].Pharmacol Res,2025,211:107544.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录